Goldman Sachs: Pharma Stocks That Need Price Hikes to Thrive Better Find a New Strategy Fast

Raising drug prices as a way to generate growth has become an increasingly risky strategy, as the Mylan ( MYL ) Epipen controversy demonstrated . Goldman Sachs analyst Jami Rubin and team argue that it's time for companies like Jazz Pharmaceuticals ( JAZZ ), Horizon Pharma ( HZNP ), and Concordia International ( CXRX ) to "reduce reliance on price increases." They explain: